首页> 美国卫生研究院文献>Oncology Letters >Proton beam therapy for locally advanced and unresectable (T4bN0M0) squamous cell carcinoma of the ethmoid sinus: A report of seven cases and a literature review
【2h】

Proton beam therapy for locally advanced and unresectable (T4bN0M0) squamous cell carcinoma of the ethmoid sinus: A report of seven cases and a literature review

机译:质子束治疗筛窦窦局部晚期不可切除的(T4bN0M0)鳞状细胞癌:七例报告并文献复习

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The present study reports treatment outcomes of locally advanced and unresectable squamous cell carcinoma of the ethmoid sinus (SCC-ES) following proton beam therapy (PBT). Between January 1997 and December 2012, 7 patients (median age, 63 years) with SCC-ES underwent definitive PBT. All tumors were categorized as T4bN0M0 (2009 UICC tumor-node-metastasis classification) and were treated using conventional fractionation at a median total dose of 72 Gy equivalents (GyE; range, 70.4–76 GyE). Imaging diagnosis for the initial treatment effect within 3 months of PBT revealed that a complete response (CR) was achieved in 2 patients and a partial response (PR) in 5 patients. The overall median survival time of the patients was 43 months (range, 12–62 months), and 4 patients survived for ≥3 years. No recurrence was observed in the 2 patients who exhibited an initial CR treatment effect; however, locoregional recurrences occurred in 4/5 patients who exhibited a PR. No grade 3 or severe acute toxicities were observed, but the late toxicities of grade 3 contralateral optic nerve damage and cataracts developed in 1 and 2 patients, respectively. Based on the findings of the present study, intensification of the local treatment effect may be important for yielding favorable treatment outcomes, since no distant metastasis was observed. PBT is therefore a potentially useful treatment tool for unresectable SCC-ES.
机译:本研究报告了质子束治疗(PBT)后筛窦窦局部鳞状上皮细胞癌(SCC-ES)的治疗结果。在1997年1月至2012年12月之间,有7例SCC-ES患者(中位年龄为63岁)接受了确定性PBT检查。所有肿瘤均归类为T4bN0M0(2009 UICC肿瘤-淋巴结转移分类),并采用常规分次治疗,中位总剂量为72 Gy当量(GyE;范围为70.4-76 GyE)。对PBT在3个月内的初始治疗效果进行影像学诊断,发现2例患者获得了完全缓解(CR),5例患者获得了部分缓解(PR)。患者的总中位生存时间为43个月(范围12-62个月),并且4例患者生存≥3年。表现出CR治疗效果的2例患者均未观察到复发。然而,局部复发在表现为PR的4/5患者中发生。没有观察到3级或严重的急性毒性,但是1和2例患者分别出现了3级对侧视神经损害和白内障的晚期毒性。根据本研究的发现,由于未观察到远处转移,因此加强局部治疗效果对于产生有利的治疗效果可能很重要。因此,PBT是不可切除SCC-ES的潜在有用治疗工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号